Roche Molecular Systems, Inc.

I'll research this company to verify its profile.

Roche Molecular Systems, Inc. — commonly "RMS," and largely synonymous with Roche Molecular Diagnostics / Roche Molecular Solutions — is a U.S. molecular-diagnostics company headquartered at 4300 Hacienda Drive, Pleasanton, California, with an additional facility in Branchburg, New Jersey. Incorporated in 1991 to commercialize Roche's acquired rights to the polymerase chain reaction (PCR), it is a wholly owned subsidiary of Swiss healthcare group Roche Holding AG (SIX: ROG; OTC: RHHBY), whose Diagnostics division reported about CHF 14.3 billion in 2024 sales and roughly 103,000 employees group-wide as of 2024. RMS is an operating subsidiary, not a standalone public company; it does not file separately with the SEC.

RMS develops and commercializes PCR-based in vitro diagnostic tests and instrument platforms for clinical laboratories and blood/tissue screening. Its major offerings include the cobas 5800/6800/8800 automated molecular testing systems and the cobas HPV test, plus PCR assays for HIV, hepatitis, CT/NG, CMV, West Nile virus and respiratory infections. Its historical technology base includes Taq DNA polymerase and related PCR reagents, which trace to Roche's 1991 purchase of PCR rights from Cetus Corporation.

Patent-litigation posture: RMS is an operating company and a patent enforcer, not a non-practicing entity. The tracked data show one case as plaintiff and zero as defendant, consistent with a diagnostics manufacturer asserting acquired IP rather than an NPE waging a volume campaign. The lone tracked venue is the U.S. District Court for the Northern District of California — not a plaintiff-friendly EDTx docket — so the single data point reflects a conventional commercial dispute.

Notable case: Hoffmann-La Roche, Inc. et al. v. Promega Corporation (N.D. Cal., filed 1992) was a license/breach dispute over Taq polymerase in which Promega counterclaimed that the underlying Taq patent (`818) was unenforceable. The district court found inequitable conduct and unenforceability (1999), the Federal Circuit vacated in part and remanded (Hoffmann-La Roche, Inc. v. Promega Corp., 323 F.3d 1354 (Fed. Cir. 2003)), and the district court again held the patent unenforceable (319 F. Supp. 2d 1011 (N.D. Cal. 2004)). The case centered on PCR/Taq technology and the 1991 Cetus acquisition.